Oral Session 13: TED

ea0101op-13-01 | Oral Session 13: TED | ETA2024

VRDN-003, a full antagonist antibody to IGF-1R for thyroid eye disease (TED): phase 1 results show potential for subcutaneous administration

Salvi Mario , Foster Kelly , Dickinson Brent , Matthew Abiola , Vijayaraghavan Jyothi , Michalsky Cathy , Bedian Vahe

Objectives: Prior phase 2 proof-of-concept results showed the clinical activity of 2 intravenous (IV) infusions of VRDN-001 in active and chronic thyroid eye disease (TED). VRDN-003 is a next-generation antibody that has the same binding epitope as VRDN-001 but includes a half-life extension modification. We present preliminary results from an ongoing phase 1 study showing the effect of VRDN-003s half-life extension on its pharmacokinetics (PK), pharmacodynamics (PD), an...

0 shares

ea0101op-13-02 | Oral Session 13: TED | ETA2024

Response to teprotumumab is independent of race, ethnicity, and age

Kahaly George J. , Wester Sara , Liu Catherine , Dai Xiaoxian , Karon Michael , Kim Sun , Conrad Elizabeth , Holt Robert J. , Hiromatsu Yuji

Objective: Thyroid eye disease (TED) patients may experience pain, proptosis and diplopia. Teprotumumab significantly improved proptosis in three trials in patients with high clinical activity score (CAS), recent-onset TED, and one trial in low CAS, longer-duration TED patients. We report pooled proptosis response in patient subgroups, and across high and low CAS trials.Methods: Patients ≥18 years from three clinical trials in the US and EU (NCT018...

0 shares

ea0101op-13-03 | Oral Session 13: TED | ETA2024

Abstract withdrawn...

0 shares

ea0101op-13-04 | Oral Session 13: TED | ETA2024

Target-tissue immunophenotyping of patients with thyroid eye disease before and after therapy with steroids, tocilizumab and rituximab

Muller Ilaria , Maioli Sara , Armenti Mirco , Crivicich Erica , Curro Nicola , Montacchini Benedetta , Mantovani Giovanna , Geginat Jens , Salvi Mario

Objectives: The treatment of active moderate-to-severe Thyroid Eye Disease (TED) consists of intravenous methylprednisolone (ivMP) as first-line, and several other immunosuppressants as second-line, including tocilizumab (TCZ) and rituximab (RTX), two humanized antibodies targeting IL6-receptor and CD20, respectively. The characterization of target-tissue-resident lymphocyte subpopulations before and after treatment might help to personalise TED treatment, by elucidating the d...

0 shares

ea0101op-13-05 | Oral Session 13: TED | ETA2024

Efficacy of teprotumumab on medical and surgical resistant don

Lucia Carretti Anna , Kielwasser Gauthier , Peiffert Mathilde , Bogaciu Teodora , Thia-Soui-Tchonga Kim , Jouanneau Emmanuel , Lasolle Helene , Castellnou Solene , Manet Romain , Abeillon-du Payrat Juliette

Dysthyroid Optic Neuropathy (DON) is a rare but sight threatening complication of Graves orbitopathy (GO), secondary to optic nerve compression or optic nerve stretching. A previous study from our group showed that medical and surgical treatment of DON according to EUGOGO guidelines resulted in a significant recovery in 70% of DON. However 30% had only partial or no recovery. Teprotumumab is an Insulin Growth Factor -1Receptor inhibitor (IGF-1R) showing impressive results in t...

0 shares

ea0101op-13-06 | Oral Session 13: TED | ETA2024

Prognostic factors and outcomes of intravenous glucocorticoid pulse therapy in moderate-to-severe thyroid eye disease

Giannakogeorgou Anna , Bobbert Thomas , Salchow Daniel J.

Objectives: The objective of our retrospective cohort study was to identify prognostic factors associated with treatment success in patients with active moderate-to-severe Thyroid Eye Disease (TED) undergoing intravenous glucocorticoid (ivGC) therapy, defined as the absence of the necessity for additional rehabilitative surgery after treatment completion. Additional objectives encompassed evaluating changes in ophthalmological parameters and thyroid-specific markers correlated...

0 shares

ea0101op-13-07 | Oral Session 13: TED | ETA2024

Long-term outcome of graves’ orbitopathy following treatment with sirolimus (RAPAMYCIN)

Comi Simone , Cosentino Giada , Lanzolla Giulia , Menconi Francesca , Novella Maglionico Maria , Posarelli Chiara , Figus Michele , Elisei Rossella , Santini Ferruccio , Marino Michele

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti- proliferative activities. Recently, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves orbitopathy (GO) at 24 weeks compared to methylprednisolone. Here we conducted a retrospective study to investigate the efficacy and safety of sirolimus compared with methylprednisolone over a longer period of time.Methods...

0 shares

Endocrine Abstracts

46th Annual Meeting of the European Thyroid Association (ETA) 2024

Oral Presentations

VRDN-003, a full antagonist antibody to IGF-1R for thyroid eye disease (TED): phase 1 results show potential for subcutaneous administration

Response to teprotumumab is independent of race, ethnicity, and age

Target-tissue immunophenotyping of patients with thyroid eye disease before and after therapy with steroids, tocilizumab and rituximab

Efficacy of teprotumumab on medical and surgical resistant don

Prognostic factors and outcomes of intravenous glucocorticoid pulse therapy in moderate-to-severe thyroid eye disease

Long-term outcome of graves’ orbitopathy following treatment with sirolimus (RAPAMYCIN)

BiosciAbstracts